References
- Nichols W C, Dwulet F E, Liepnieks J, Benson M D. Variant apolipoprotein AI as a major constituent of human hereditary amyloid. Biochem Biophys Res Commun 1988; 156: 762–768
- Jones L A, Harding J A, Cohen A S, Skinner M. New USA family has apolipoprotein Al (Arg 26) variant. Amyloid and Amyloidosis 1990, J B Natvig, O Forre, G Husby, A Husebekk, B Skogen, K Sletten, P Westerrnark. Kluwer Academic Publishers, DordrechtThe Netherlands 1990; 385–388
- Soutar A K, Hawkins P N, Vigushin D M, Tennent G A, Booth S E, Hutton T, Nguyen O, Totty N F, Feest T G, Hsuan J J, Pepys M B. Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. Proc Natl Acad Sci USA 1992; 89: 7389–7393
- Johnson K H, Sletten K, Hayden D W, O'Brien T D, Roertgen K E, Westermark P. Pulmonary vascular amyloidosis in aged dogs. Am J Pathol 1992; 141: 1013–1018
- Wisniewski T, Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neumsc Ltrs 1992; 135: 235–238
- Corder E H, Saunders A M, Strittmatter W J, Schmechel D E, Gaskell P C, Small G W, Roses A D, Haines J L, Pericak-Vance M A. Gene dose of apolipoprotein E Type 4 allele and the risk ofAlzheimer's Disease in late onset families. Science 1993; 261: 921–923
- Jacobson D R, Buxbam J N. Genetic aspects of amyloidosis. Adv Hum Genet 1991; 20: 69–123